Skip to content
AgingNexus
☰ Menu
Open access · CC-BY via OpenAlex

Development of a novel senolytic by precise disruption of FOXO4-p53 complex

Utkarsh Tripathi, Selim Chaib, Erin O. Wissler Gerdes, Kelly Hogan, Yi Zhu

EBioMedicine · 2021 · ▲ 8 citations

Cellular senescence Senolytics Human Mouse Preclinical / animal Review
＋ Sign in to save

Abstract

The first senolytic agents, senescent cell-eliminating drugs Dasatinib, Quercetin, Fisetin, and Navitoclax were discovered through a hypothesis-driven approach [2–5]: Senescent cells remain viable by inactivating senescence(definition) cell anti-apoptotic pathways (SCAPs) including ephrins, PI3K isoforms, p53/p21CIP1, HIF-1α, plasminogen activated inhibitors 1 and 2, and Bcl-2 family members [2]. Therefore, the first senolytics(definition) were developed to target SCAP signalling.

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/j.ebiom.2021.103693
Canonical
link ↗
Fetched
2026-07-29 MST

Cite this

APA
Tripathi, U., Chaib, S., Gerdes, E.O.W., Hogan, K., &amp; Zhu, Y. (2021). Development of a novel senolytic by precise disruption of FOXO4-p53 complex. <em>EBioMedicine</em>. https://doi.org/10.1016/j.ebiom.2021.103693
Vancouver
Tripathi U, Chaib S, Gerdes EOW, Hogan K, Zhu Y. Development of a novel senolytic by precise disruption of FOXO4-p53 complex. EBioMedicine. 2021. doi:10.1016/j.ebiom.2021.103693.
BibTeX
@article{utkarsh2021Develo, title = {Development of a novel senolytic by precise disruption of FOXO4-p53 complex}, author = {Utkarsh Tripathi and Selim Chaib and Erin O. Wissler Gerdes and Kelly Hogan and Yi Zhu}, journal = {EBioMedicine}, year = {2021}, doi = {10.1016/j.ebiom.2021.103693}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings